Radiation boosts immunotherapy in kidney cancer trial
NCT ID NCT04090710
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding precise, high-dose radiation (SBRT) to standard immunotherapy (ipilimumab and nivolumab) can help people with metastatic kidney cancer live longer without their disease getting worse. About 66 participants with intermediate or poor-risk disease will either get immunotherapy alone or immunotherapy plus radiation to their primary kidney tumor. The study is active but no longer recruiting, and results are expected to show if the combination improves progression-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ipilimumab (Yervoy) and Nivolumab (Opdivo) with or without stereotactic body radiation therapy (SBRT)
What this could lead to
If it works, this could show that adding targeted radiation to immunotherapy helps control metastatic kidney cancer longer than immunotherapy alone.
What could go wrong
This is a mid-stage trial with only 66 participants, so results may not apply to everyone. Adding radiation may increase side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
Grand River Regional Cancer Centre
Kitchener, Ontario, N2G1G3, Canada
-
Juravinski Cancer Centre
Hamilton, Ontario, Canada
-
London Regional Cancer Centre
London, Ontario, N2G1G3, Canada
-
Peter MacCallum Cancer Centre
Melbourne, 3000, Australia
-
Sunnybrook Health Sciences Centre- Odette Cancer Centre
Toronto, Ontario, M4N3M5, Canada
-
The Ottawa Regional Cancer Centre
Ottawa, Ontario, K1H8L6, Canada